Black Diamond Therapeutics 推出了 BDTX-1535，这是一款第四代 TKI，针对更广泛的 EGFR 突变，包括 NSCLC 患者的非经典突变。 Black Diamond Therapeutics unveils BDTX-1535, a fourth-generation TKI targeting broader EGFR mutations, including non-classical ones in NSCLC patients.
Black Diamond Therapeutics在AACR年会上报告称，NSCLC患者中非经典EGFR突变可达20-30%。 Black Diamond Therapeutics presented at AACR Annual Meeting, revealing that non-classical EGFR mutations in NSCLC patients can reach 20-30%. 他们的药物 BDTX-1535 是一种第四代 TKI，针对更广泛的突变，解决经典和非经典 EGFR 突变，包括 C797S 等耐药突变。 Their drug BDTX-1535, a fourth-generation TKI, targets a broader range of mutations, addressing classical and non-classical EGFR mutations, including resistance mutations like C797S. 这使得它成为第一个也是同类最佳的第四代 EGFR 抑制剂。 This makes it the first and best-in-class fourth-generation EGFR inhibitor.